Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

The company offers year-round educational services on the conditions, using this month in particular to guide patients to ...

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to ...

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye. AI Optics, an ...

Editor's note: The below transcript has been lightly edited for clarity. Ramiro Ribeiro, MD, PhD: Sure So at Hawaiian Eye, we gave an update on our phase 2 program, the Davio-2 study, that is the ...

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden. Basically, we were looking at the ...

Korean investigators reported that faricimab (Vabysmo, Roche/Genentech) in a real-world setting works well for patients with neovascular age-related macular degeneration (nAMD) refractory to other ...

4D Molecular Therapeutics announced it will present the initial interim 52-week data from the Phase 2b Population Extension cohort of the PRISM clinical trial. The trial is evaluating 4D-150 in a ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?